Zhifei Biotech announced that the clinical trial application for the pandemic influenza virus mRNA vaccine developed by the wholly-owned subsidiary Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. has been accepted by the State Drug Administration. Within 60 days from the date of acceptance, if no negative or questioning opinions are received from the Drug Review Center, Zhifeilong Koma may conduct clinical trials according to the submitted plan. The company said that as of the announcement, no mRNA vaccine for the pandemic influenza virus had been officially approved for marketing in China. Acceptance of the application will not have a significant impact on the company's recent performance, and there is uncertainty about the progress, results, and product launch status of subsequent clinical trials.

Zhifei Biotech announced that the clinical trial application for the pandemic influenza virus mRNA vaccine developed by the wholly-owned subsidiary Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. has been accepted by the State Drug Administration. Within 60 days from the date of acceptance, if no negative or questioning opinions are received from the Drug Review Center, Zhifeilong Koma may conduct clinical trials according to the submitted plan. The company said that as of the announcement, no mRNA vaccine for the pandemic influenza virus had been officially approved for marketing in China. Acceptance of the application will not have a significant impact on the company's recent performance, and there is uncertainty about the progress, results, and product launch status of subsequent clinical trials.